Besides, CRISPR/Cas9 has currently been noticed as a therapeutic solution for Alzheimer’s diseases (AD) by affecting particular AD-related genes such as those that cause early-onset AD, concurrently those that are substantial risk factors for late-onset AD (e.g., apolipoprotein E4 (APOE4) gene) (Rohn et al., 2018). Here, APOE is linked to Alzheimer disease.